World Generics Market Report 2011: Episcom Report

The World Generic Market Report 2011

World Leaders in Health Industry Analysis

World Generic Market Report 2011 Vol I: Company Profiles

Central and Eastern Europe In the 2008/09 fiscal year, Egis sales to the Central and Eastern Europe region, using its own US dollar exchange rate figures, were worth around US$122.3 million, making this the firm's second largest international market. However, as with Russia and the CIS, sales in the latest fiscal year fell, this time by 7%, from the US$132.1 million reported a year earlier. However, in constant currency terms, sales increased by 9%, and Egis noted that the increase was the result of new products and further development of its commercial network. Egis: Fiscal Year Exports to Central and Eastern Europe, in US$000s

Year ended 30th September Poland Czech Republic Slovakia Latvia & Lithuania Romania Bulgaria Turkey Vietnam Total 2006 36,336 14,678 10,192 2,021 15,364 5,625 3,487 87,703 2007 40,650 17,230 12,862 2,836 17,293 6,642 3,608 101,121 2008 51,828 24,106 18,379 3,312 21,893 7,704 1,248 3,670 132,140 2009 47,734 22,387 18,501 3,352 15,953 6,508 3,998 3,875 122,308

Vietnam is included by Egis in the CEE region for accounting purposes.

Western Europe Using its own US dollar exchange rate figures, Egis reported that its turnover in Western Europe was worth US$68.7 million in fiscal year 2008/09, representing a fall of 19% over the prior year period, when sales were worth US$84.8 million. The firm commented that within this, sales of bulk chemicals were worth US$36.4 million, a drop of US$26.2 million compared to FY2007/08. However, the value of drug sales reached US$32.3 million, up by 45% over the prior year. Egis commented that a large part of this increase was attributable to its alliance with Servier. Egis: Full Year Exports, Fiscal Year to 30th September, to Western Europe in US$000s

Year ended 30th September France UK Netherlands Ireland Norway Germany Other countries Total 2006 14,402 2,922...